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1 Saint Louis University School of Medicine, St. Louis, MO, USA, 2 Department of Psychiatry, Washington University Medical 
School, St. Louis, MO, USA
Early identification and treatment are associated with improved outcomes in bipolar 
disorder (BPD) and schizophrenia (SCZ). Screening for the presence of these disorders 
usually involves time-intensive interviews that may not be practical in settings where 
mental health providers are limited. Thus, individuals at earlier stages of illness are 
often not identified. The Washington Early Recognition Center Affectivity and Psychosis 
(WERCAP) screen is a self-report questionnaire originally developed to identify clinical 
risk for developing bipolar or psychotic disorders. The goal of the current study was to 
investigate the utility of the WERCAP Screen and two complementary questionnaires, 
the WERC Stress Screen and the WERC Substance Screen, in identifying individuals with 
established SCZ or BPD. Participants consisted of 35 BPD and 34 SCZ patients, as well 
as 32 controls (CON), aged 18–30 years. Univariate analyses were used to test for score 
differences between groups. Logistic regression and receiver operating characteristic 
(ROC) curves were used to identify diagnostic predictors. Significant group differences 
were found for the psychosis section of the WERCAP (pWERCAP; p < 0.001), affective 
section of the WERCAP (aWERCAP; p = 0.001), and stress severity (p = 0.027). No 
significant group differences were found in the rates of substance use as measured by 
the WERC Substance Screen (p = 0.267). Only the aWERCAP and pWERCAP scores 
were useful predictors of diagnostic category. ROC curve analysis showed the optimal 
cut point on the aWERCAP to identify BPD among our participant groups was a score 
of >20 [area under the curve (AUC): 0.87; sensitivity: 0.91; specificity: 0.71], while that 
for the pWERCAP to identify SCZ was a score of >13 (AUC: 0.89; sensitivity: 0.88; 
specificity: 0.82). These results indicate that the WERCAP Screen may be useful in 
screening individuals for BPD and SCZ and that identifying stress and substance-use 
severity can be rapidly done using self-report questionnaires. Larger studies in undiag-
nosed individuals will be needed to test the WERCAP Screen’s ability to identify mania 
or psychosis in the community.
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inTrODUcTiOn
Schizophrenia (SCZ) and bipolar disorder (BPD) are complex 
mental illnesses with onset in adolescence and are among the 
leading causes of disability worldwide (1). Early identification and 
initiation of antipsychotic therapy are associated with improved 
prognoses in SCZ, whereas longer durations of untreated illness 
are associated with worse outcomes (2, 3). This holds true across 
different nations and cultures (4, 5). Similarly, in BPD, delayed 
diagnosis and treatment are associated with more hospitaliza-
tions, increased suicidality (6), and impaired social function (7). 
Patients with recurrent depressive episodes in BPD may be misdi-
agnosed with unipolar depression, leading to a longer duration of 
untreated illness and worse outcomes (8–10). Misdiagnosis and 
inappropriate treatment with antidepressants can increase mania 
and exacerbation of the episode (11). In some practices, it takes an 
average of about 10 years between the onset of BPD and initiation 
of treatment with mood stabilizers (12). The challenges involved 
in early recognition and treatment of SCZ and BPD support the 
need for a reliable screening instrument.
Bipolar disorder and SCZ are typically diagnosed by a clinician 
or by structured clinical interviews, which are time consuming 
and, therefore, not practical for screening purposes. Commonly 
used screening questionnaires in BPD, such as the Altman Self-
Rating Mania Scale (13), Young Mania Rating Scale (14), or the 
Bipolar Spectrum Diagnostic Scale (BSDS) (15), either probe for 
severity of current manic-like symptoms or generate unacceptably 
high rates of false positives and low sensitivity (16). For example, 
the Mood Disorders Questionnaire, the most extensively studied 
of instruments for detecting BPD, was found to have a positive 
predictive value (PPV) of 22.1% (17). Likewise, the BSDS has a 
PPV of only 16% (18). Thus, the need for a rapid and reliable 
means to screen for BPD remains unmet. Similarly, the commu-
nity assessment of psychic experiences (CAPE)-42, a screening 
instrument for detecting psychosis, has a PPV of only 23.5% (19). 
Other rating instruments commonly used in assessing SCZ or 
other psychotic disorders, such as the Scale for the Assessment of 
Positive Symptoms (20) or the Positive and Negative Syndrome 
Scale (21), probe for current psychotic symptoms and are not 
designed to assist in diagnosis.
The Washington Early Recognition Center Affectivity and 
Psychosis (WERCAP) screen was developed to accurately and 
efficiently identify individuals at risk of bipolar and psychotic 
disorders. The WERCAP Screen is a quantitative measure of 
affective and psychotic symptoms that elicits information about 
symptom frequency and the degree of resulting dysfunction 
(“functionality”). The WERCAP Screen has been validated in a 
non-clinical youth population in the US, provides results com-
parable to the structured interview for prodromal syndromes 
(SIPS) in a much shorter period of time, and is designed to be 
cross-culturally applicable (22). The WERCAP Screen has two 
sections, the aWERCAP and pWERCAP, which measure the risk 
of developing BPD (“affectivity”) and psychosis, respectively. 
Unlike other screening instruments, the WERCAP Screen was 
designed to assess chronic or lifetime affective or psychotic 
symptoms (although a time interval can be specified for more 
acute symptoms). Thus, it could potentially be used to identify 
individuals with established bipolar or psychotic disorder diag-
noses and also inform on illness severity.
Stress (23) and substance use (24) are both associated with 
risk of psychosis and decompensation in those with psychotic 
or BPDs; thus, reliably assessing their severities could provide 
valuable information for clinicians. A number of substances 
have been found to be associated with risk of psychosis and BPD, 
most commonly tobacco (25, 26) and cannabis (27). There is 
now strong evidence suggesting that cannabis use can trigger the 
onset of psychosis (28–30). Progression to greater cannabis usage 
frequency is associated with greater risk of psychosis (31). Higher 
rates of cannabis use have been consistently linked with earlier 
age of onset in psychosis (30, 32–35) with some studies reporting 
a similar association in BPD (36–38).
Substance use has also been reported to exacerbate symptoms 
in patients that have already been diagnosed with SCZ and BPD. 
SCZ patients with a history of cannabis use tend to have longer 
hospital stays and more frequent readmissions compared to can-
nabis non-users (39). Cannabis use is also linked with an increase 
in psychotic (40–43) and manic symptoms (44). Cannabis use 
is associated with worse treatment outcomes and functioning in 
patients with psychosis (45–47) and BPD (48, 49). Some studies 
have also found tobacco use to be associated with greater illness 
severity (50). Tobacco smoking is highly prevalent among SCZ 
and bipolar patients (51) and has been associated with worse 
outcomes and lower remission rates in BPD (49, 52). In addi-
tion, there have been case reports of psychiatric relapse following 
excessive caffeine consumption in patients suffering from SCZ 
(53) and BPD (54).
Psychosocial stress is another risk factor shared between SCZ 
and BPD, along with other psychiatric disorders (55, 56). There is 
extensive evidence linking early childhood trauma with increased 
risk of psychosis (57–59) and BPD (60). It has been hypothesized 
that childhood adversity results in increased vulnerability to 
stress and psychiatric disorder (61). SCZ, BPD, and depression 
patients all tend to report increased sensitivity to stress (62). 
Moreover, greater exposure to childhood adversity has been 
correlated with higher levels of perceived stress and increased 
psychopathology (63). Stressors later in life have also been 
found to increase the risk of psychotic (64) and manic (65–67) 
episodes. More recent studies have reported everyday stressors 
in adult life to be correlated with an increase in psychotic (68) 
and manic (69) symptoms. Thus, assessing stress severity could 
conceivably improve the identification of individuals at risk for 
psychosis and BPD.
We have previously developed tools to capture psychoso-
cial stress load and substance-use habits. The WERC Stress 
Screen (hereafter referred to as “Stress Screen”) is a self-report 
questionnaire that assesses the overall stress burden currently 
experienced by the individual, and also quantifies the individual 
contributions of common psychosocial stressors to the total 
stress burden (22). The WERC Substance Screen (hereafter 
referred to as “Substance Screen”) allows respondents to self-
report on the usage frequencies of multiple substances that may 
influence brain function.
The current study explores the utility of our quantitative 
screening instruments in a sample of patients with SCZ and 
TaBle 1 | Demographics for each diagnostic group.
control (N = 32) Bipolar (N = 35) schizophrenia (N = 34) Total (N = 101)
Mean age (SD) 24.1 (3.03) 25.1 (3.48) 25.8 (3.44) 25.0 (3.37)
characteristic N (%) N (%) N (%) N (%)
gender
Female 20 (62.5) 25 (71.4) 7 (20.6) 52 (52.5)
Male 12 (37.5) 10 (28.6) 27 (79.4) 49 (48.5)
ethnicity
American Indian/Alaskan native 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Asian 3 (9.4) 3 (8.6) 0 (0.0) 6 (5.9)
Black/African-American 11 (34.0) 7 (20.0) 21 (62.4) 39 (38.6)
Native Hawaiian/Pacific Islander 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
White 17 (53.1) 24 (68.6) 11 (31.4) 52 (51.0)
Biracial/Multiracial 1 (3.1) 1 (2.9) 1 (2.9) 3 (3.0)
Other/unknown 0 (0.0) 0 (0.0) 1 (2.9) 1 (1.0)
employment
Full time 15 (46.9) 12 (34.3) 1 (2.9) 28 (27.7)
Part time 6 (18.8) 6 (17.1) 7 (20.0) 19 (18.8)
Unemployed 2 (6.3) 8 (22.9) 21 (61.8) 31 (30.7)
Full-time student 6 (18.8) 5 (14.3) 4 (11.4) 15 (14.9)
Part-time student 3 (9.4) 3 (8.6) 0 (0.0) 6 (5.9)
Other 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.0)
level of education
Graduate professional training 5 (15.6) 4 (11.4) 0 (0.0) 9 (8.9)
College/university graduate 10 (31.3) 7 (20.0) 1 (2.9) 18 (17.8)
Partial college 14 (43.8) 18 (51.4) 15 (44.1) 47 (46.5)
High school graduate 0 (0.0) 5 (14.3) 13 (38.2) 18 (17.8)
Partial high school 3 (9.4) 1 (2.9) 3 (8.8) 7 (6.9)
Junior high school 0 (0.0) 0 (0.0) 1 (2.9) 1 (1.0)
Less than 7 years of school 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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BPD. Our objective was to determine whether the WERCAP 
Screen, Stress Screen, or Substance Screen could predict diag-
nosis in a clinical population and the optimal cutoff thresholds 
on these instruments. We hypothesized that the measures of 
psychosis and affectivity would be the most useful predictors 
of diagnosis.
MaTerials anD MeThODs
The Institutional Review Board of Washington University Medical 
School in St. Louis approved all procedures and study materials. 
All participants in the study provided informed consent.
Participants
One hundred two individuals ages 18–30 years participated in the 
study, which consisted of three groups: BPD (BPD, n = 35), SCZ 
(SCZ, n = 34), and healthy controls (CON, n = 32). Participants 
were recruited using a combination of flyers posted in public 
locations, recruitment information posted to university websites, 
as well as clinic referrals. Consequently, our sample size was 
limited by clinical availability of individuals with SCZ and BPD 
who met inclusion criteria. Diagnosis was determined based 
on the agreement of assessments by a research psychiatrist and 
a trained research assistant using the structured clinical inter-
view for DSM-IV axis I disorders (SCID-I) and the structured 
clinical interview for DSM-IV axis II disorders (SCID-II), with 
precedence given to the psychiatrist’s determination. Exclusion 
criteria during initial screening included (1) a history of substance 
dependence or substance abuse during the 6  months prior to 
participation, (2) a currently unstable clinical disorder or severe 
general medical disorder, or (3) a history of head injury, multiple 
seizures, or concussions resulting in unconsciousness for more 
than 30 min. Table 1 presents demographic information for the 
three participant groups.
Werc screening Forms
Participants completed three screening forms: the WERCAP 
Screen, the Stress Screen (22), and the Substance Screen. These 
forms are available for public use (http://werc.wustl.edu/home/
screeninginstruments).
The WERCAP Screen assesses risk of BPD and psychosis 
based on a quantification of lifetime symptom burden. The 
WERCAP Screen consists of a total of 16 questions, the first 
half of which are designed to assess affective symptoms experi-
enced by individuals, while the remaining questions assess risk 
of psychosis. The majority of questions (10 out of 16) require 
two responses, including a rating of the frequency of symptom 
occurrence, and if present, the severity of the associated func-
tional impairment. For the item probing into decreased need 
for sleep, respondents were asked to rate symptom duration 
rather than degree of functional impairment. Six questions in 
the affectivity section assess only symptom frequency, since they 
4Hsieh et al. Utility of WERC Self-Report Questionnaires
Frontiers in Psychiatry | www.frontiersin.org August 2016 | Volume 7 | Article 149
inquire about symptoms that do not typically impair function, 
or the degree of resulting dysfunction is difficult to assess. The 
responses were converted into numerical values as follows: 
No = 0, Once = 1, Rarely (<yearly) = 2, Sometimes (>yearly–
monthly) = 3, Often (>monthly–weekly) = 4, and Almost Always 
(>weekly–daily) = 5. For items assessing effect on functionality, 
responses were converted as follows: Not at All = 0, A Little = 1, 
Moderately =  2, Severely =  3. The frequency and functional-
ity scores for items 1–8 were summed to generate a composite 
aWERCAP (affectivity) score, and the remaining items (9–16) 
were summed to generate the composite pWERCAP (psychosis) 
score. The maximum aWERCAP score possible is 49, and the 
maximum pWERCAP score is 64, yielding a maximum total 
WERCAP Screen score of 113.
The Stress Screen assesses the total stress burden of 23 com-
mon psychosocial stressors, such as one’s relationships with 
family and friends, substance use, or the workplace [see Ref. 
(22) for a complete list]. Space is also provided to write in up to 
two additional stressors. By default, the Stress Screen is designed 
to capture the current stress load on an individual. Respondents 
are asked to rate the extent to which they are affected by each 
stressor by marking the appropriate checkbox. Each response 
is converted to a numerical rating (No  =  0, A Little  =  1, 
Moderate = 2, A Lot = 5, Severely = 10), and then summed to 
generate the Stress Screen score. The maximum Stress Screen 
score possible is 230.
The Substance Screen is a 20-item questionnaire that assesses 
the current substance-use habits of the respondent. Respondents 
were asked to rate their usage frequency of a variety of psycho-
tropic substances, such as caffeine, nicotine, prescription drugs, 
etc. [see Ref. (22) for a complete list] and could also choose to 
write in up to two additional substances. The frequency responses 
were converted into a numerical score using the same scale as 
that in the WERCAP Screen, and then summed to generate the 
Substance Screen score.
Data analysis
Statistical analyses were performed using IBM’s SPSS software 
(IBM SPSS Statistics for Macintosh, Version 24.0, Armonk, NY, 
USA). Demographic differences between diagnostic groups 
were assessed with one-way ANOVAs treating diagnosis as a 
fixed factor or chi-square (χ2) tests as appropriate. Between-
group differences in aWERCAP, pWERCAP, and Stress Screen 
scores were examined using univariate analysis of covariance 
(ANCOVA) tests, including gender, age, and years of education 
as covariates, followed by post hoc pairwise tests, corrected for 
multiple comparisons treating diagnostic group as a fixed effect.
We utilized logistic regression to examine the capability of 
the aWERCAP, pWERCAP, WERC Stress Screen, and number 
of substances used to predict diagnostic group. The number of 
substances measured by the Substance Screen was used in the 
logistic regression instead of a Substance Screen score derived 
from summing all substance usage frequencies, due to substantial 
potency variability of the different substances. Only the most 
prevalent substances used by our participants were included in 
the logistic regression (i.e., tobacco, coffee, other caffeinated bev-
erages, alcohol, and cannabis). Receiver Operating Characteristic 
(ROC) curves were generated for aWERCAP and pWERCAP to 
study classification with varying thresholds and determine the 
thresholds with optimum sensitivity and specificity. Substance 
and Stress Screen scores were not predictive of diagnostic group 
membership in the logistic regressions and, therefore, were not 
considered for this analysis.
resUlTs
Demographics
Demographic information for each diagnostic group is presented 
in Table  1. Mean age was not significantly different between 
groups (F(2,98) = 1.848, p = 0.163). However, there were signifi-
cant differences in gender (χ2 = 20.122, p < 0.001) and ethnicity 
(χ2 = 17.465, p = 0.026) between groups. Psychiatric comorbidi-
ties in each group are shown in Table 2.
WercaP screen
Univariate analyses showed significant group effects for 
aWERCAP (F(2,92)  =  52.904, p  <  0.001) and pWERCAP 
(F(2,92)  =  50.378, p  <  0.001, η2  =  0.523), but not for stress 
or substance scores. The relationship between individual 
aWERCAP, pWERCAP, and Stress Screen scores is depicted 
in Figure 1. Average scores for each of the screens are shown in 
Table 3. Pairwise comparisons between diagnoses, Bonferroni 
correcting for multiple comparisons, showed that BPD had 
significantly higher aWERCAP scores than CON (p <  0.001) 
and SCZ (p =  0.001). Scores on the aWERCAP in SCZ were 
also higher than in CON (p < 0.001). pWERCAP scores were 
significantly higher in SCZ compared to BPD (p  <  0.001) 
and CON (p <  0.001), as well as in BPD compared to CON 
(p = 0.001). Mean aWERCAP scores did not significantly differ 
between genders (t = 0.691, p = 0.491). Mean aWERCAP item 
scores broken down by sex and diagnosis are shown in Figure 2. 
Males experienced significantly higher total psychotic symptom 
scores than females (t = −2.324, p = 0.022). Mean pWERCAP 
item scores for males and females in each diagnostic group are 
shown in Figure 3.
stress screen
Univariate analysis of Stress Screen scores showed a significant 
main effect of diagnostic group (F(2,92) = 3.740, p = 0.027). Mean 
Stress Screen item scores for each diagnostic group are shown in 
Figure 4. Pairwise comparisons showed that BPD had significantly 
higher Stress Screen scores than the CON (p = 0.033). However, 
BPD did not significantly differ from the SCZ on stress severity. 
SCZ did not significantly differ from CON on stress severity 
(p = 0.182). We found no significant differences in WERC Stress 
scores across genders (t = 0.541, p = 0.589).
substance screen
A comparison of the rate of substance use showed only a marginal 
effect of diagnosis (F(2,92) = 2.987, p = 0.055). BPD reported using 
significantly more substances than CON (p =  0.015) or SCZ 
(p = 0.032). There was no significant difference in the number 
of substances used between the CON and SCZ. SCZ reported 
tobacco use at significantly higher rates than CON (p = 0.021). 
TaBle 2 | Prevalence of psychiatric disorders for each diagnostic group (N = 101).
control (N = 32) Bipolar (N = 35) schizophrenia (N = 34) Total (N = 101)
Psychiatric diagnosis N (%) N (%) N (%) N (%)
No diagnosis 30 (93.8) 1 (2.9) 0 (0) 31 (30.7)
Mood disorders 2 (6.25) 33 (94.3) 0 (0) 35 (34.7)
Major depressive disorder 2 (6.25) 0 (0) 0 (0) 2 (2.0)
Bipolar disorder 0 (0) 33 (94.3) 0 (0) 33 (32.7)
Anxiety disorders 0 (0) 30 (85.7) 19 (55.9) 49 (48.5)
Generalized anxiety disorder 0 (0) 3 (8.6) 5 (14.7) 8 (7.9)
Panic disorder 0 (0) 2 (5.7) 1 (2.9) 3 (3.0)
Panic disorder w/agoraphobia 0 (0) 0 (0) 3 (8.8) 3 (3.0)
Agoraphobia w/o panic disorder 0 (0) 4 (11.4) 5 (14.7) 9 (8.9)
PTSD 0 (0) 7 (20.0) 4 (11.8) 11 (10.9)
Social phobia 0 (0) 10 (28.6) 2 (5.9) 12 (11.9)
Specific phobia 0 (0) 4 (11.4) 2 (5.9) 6 (5.9)
Obsessive compulsive disorders 0 (0) 0 (0) 1 (2.9) 1 (1.0)
Obsessive compulsive disorder 0 (0) 0 (0) 1 (2.9) 1 (1.0)
Body dysmorphic disorder 0 (0) 0 (0) 0 (0) 4 (4.0)
Personality disorders 0 (0) 22 (62.9) 9 (26.5) 31 (30.7)
Borderline PD 0 (0) 5 (14.3) 2 (5.9) 7 (6.9)
Avoidant PD 0 (0) 8 (22.9) 4 (11.8) 12 (11.9)
Schizotypal PD 0 (0) 0 (0) 1 (2.9) 1 (1.0)
Obsessive compulsive PD 0 (0) 5 (14.3) 1 (2.9) 6 (5.9)
Antisocial PD 0 (0) 1 (2.9) 0 (0) 1 (1.0)
Dependent PD 0 (0) 3 (8.6) 1 (2.9) 4 (4.0)
Paranoid PD 0 (0) 5 (14.3) 4 (11.8) 9 (8.9)
Narcissistic PD 0 (0) 3 (8.6) 1 (2.9) 4 (4.0)
Psychotic disorders 0 (0) 1 (2.9) 34 (100.0) 35 (34.7)
Schizoaffective disorder 0 (0) 1 (2.9) 4 (11.8) 5 (5.0)
Schizophrenia 0 (0) 0 (0) 29 (85.3) 29 (28.7)
Psychosis NOS 0 (0) 0 (0) 1 (2.9) 1 (1.0)
Substance-related disorders 0 (0) 0 (0) 2 (5.9) 2 (2.0)
Cannabis abuse 0 (0) 1 (2.9) 2 (5.9) 3 (3.0)
Cannabis dependence 0 (0) 0 (0) 0 (0) 0 (0.0)
Alcohol abuse 0 (0) 0 (0) 0 (0) 0 (0.0)
Alcohol dependence 0 (0) 0 (0) 0 (0) 0 (0.0)
Opioid dependence 0 (0) 0 (0) 0 (0) 0 (0.0)
Polysubstance abuse 0 (0) 0 (0) 0 (0) 0 (0.0)
Hallucinogen dependence 0 (0) 0 (0) 0 (0) 0 (0.0)
Stimulant dependence 0 (0) 0 (0) 0 (0) 0 (0.0)
Eating disorders 0 (0) 2 (5.7) 0 (0) 2 (2.0)
Bulimia nervosa 0 (0) 1 (2.9) 0 (0) 1 (1.0)
Binge eating disorder 0 (0) 1 (2.9) 0 (0) 1 (1.0)
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BPD had significantly higher coffee consumption rates than 
SCZ (p = 0.02). We found no significant differences in the rates 
of substance use as measured by the WERC Substance Screen 
(t = 1.117, p = 0.267).
logistic regression – Predicting 
Diagnostic group
Overall, logistic regression models using the aWERCAP, pWER-
CAP, Stress Screen, and number of substances used as predictors 
correctly predicted diagnosis in 89.1% of participants. Specifically, 
the model correctly predicted 93.8% of CON, 85.7% of BPD, 
and 88.2% of SCZ. However, only the aWERCAP (χ2 = 47.835, 
p < 0.001) and pWERCAP (χ2 = 79.974, p < 0.001) scores were 
useful predictors of diagnostic category, whereas the Stress 
Screen (χ2 = 2.587, p = 0.274) and number of substances used 
(χ2 = 2.918, p = 0.232) did not significantly contribute to group 
prediction. Only the aWERCAP score significantly predicted 
BPD (p <  0.001), and only the pWERCAP score significantly 
predicted SCZ (p = 0.001). Results of the logistic regression are 
presented in Table 4.
rOc curves for WercaP
To evaluate the discriminative power of the WERCAP screen to 
detect BPD and SCZ, ROC curves were calculated for aWERCAP 
and pWERCAP (see Figure 5). For detecting BPD, aWERCAP 
performed significantly better than chance, with an area under the 
curve (AUC) of 0.873 (p < 0.001); however, pWERCAP was not 
significantly better than chance at detecting BPD (AUC = 0.524, 
p =  0.695). The optimal cutoff on the aWERCAP to identify 
BPD was 20 (Table 5). At this cut point, sensitivity was 0.91 and 
specificity was 0.71.
For detecting SCZ, pWERCAP demonstrated an AUC of 0.894 
(p < 0.001), indicating that pWERCAP has very good discrimina-
tion for SCZ. aWERCAP was not significantly better than chance 
TaBle 3 | Mean (sD) Werc screen scores and number of substances 
used in each diagnostic category.
control Bipolar schizophrenia
Stress Screen 24 (34) 46 (37) 39 (28)
Number of substances 3.3 (0.4) 4.7 (0.4) 3.4 (0.4)
aWERCAP 7.1 (8.1) 29.2 (7.8) 19.0 (11.0)
pWERCAP 0.8 (3.1) 13.2 (12.3) 31.8 (16.8)
FigUre 1 | 3D scatter-plot showing stress screen scores, aWercaP composite scores, and pWercaP composite scores in each diagnostic group.
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at detecting SCZ (AUC = 0.504, p = 0.951). The optimal cutoff 
on the pWERCAP to identify SCZ in this study population was 
13 (Table 5). At this cut point, sensitivity was 0.88 and specificity 
was 0.82.
DiscUssiOn
A goal of this study was to test whether the WERC questionnaires 
could reliably identify participants with BPD and SCZ. We first 
investigated performance on these questionnaires by participants 
with these diagnoses and controls. There was a significant main 
effect of diagnosis for WERCAP scores, stress severity, and the 
number of substances used. As we predicted, individuals with 
BPD scored significantly higher on the affective symptoms 
(aWERCAP) than the control or SCZ groups. The SCZ group, 
however, had higher affective symptoms than controls, consist-
ent with the increased affective symptoms (primarily depressive 
symptoms) often seen in SCZ patients (70–76). Both of our 
patient groups also had higher psychotic symptoms (pWERCAP) 
than the control group, with the SCZ patients having the most 
severe symptoms. The BPD group, however, reported the most 
significant psychosocial stress severity, as well as the most sub-
stances used. This is consistent with results from previous studies 
showing BPD with a higher prevalence of substance-use disorders 
(SUDs) than any other psychiatric disorder (77). A high Stress 
Screen score may not necessarily indicate greater stress reactivity 
to everyday stressors. Higher sensitivity to stress has been associ-
ated with psychosis risk (78–80) and also has been reported in 
SCZ (81) as well as BPD (82). In addition, several reports have 
associated childhood adversity with risk of psychosis (58, 83), 
suggesting the importance of documenting lifetime stressors. 
Abnormalities in the hypothalamic–pituitary–adrenal axis, a key 
mediator of the stress response, have been implicated in both SCZ 
(84) and BPD (85, 86). Stress hypersensitivity and psychosocial 
stress increase susceptibility to SCZ (87, 88) and BPD (89, 90) 
FigUre 3 | Mean pWercaP screen individual item scores (frequency) in males vs. females of each diagnostic group, with standard error bars. 
x-axis = individual pWERCAP items, y-axis = mean pWERCAP frequency score, derived by summing and averaging the frequency responses in the psychosis section.
FigUre 2 | Mean aWercaP screen individual item scores (frequency) in males vs. females of each diagnostic group, with standard error bars. 
x-axis = individual aWERCAP items, y-axis = mean aWERCAP frequency score, derived by summing and averaging the frequency responses in the affectivity section.
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and also exacerbate symptoms in both disorders (91). Index 
manic (69) and psychotic (92) episodes are often preceded by an 
increase in stressful life events. Thus, the WERCAP Stress Screen 
may be a useful tool for schools and clinics in monitoring at-risk 
individuals to prevent onset or relapse.
The affectivity (aWERCAP) score alone identified individu-
als with BPD in our sample with high sensitivity and specificity, 
suggesting that the aWERCAP may be useful for detecting BPD 
in larger settings. Our current findings indicated a minimum 
aWERCAP cutoff score of 20 for detection of BPD diagnosis, 
below which an individual would be unlikely to have this 
diagnosis. Higher scores, however, do not necessarily imply 
a diagnosis of BPD, as there are likely other conditions that 
could be associated with severe affective symptoms. While not 
addressed in the current study, it is plausible, for example, 
that individuals with certain personality disorders that involve 
mood lability, such as borderline personality disorder, may 
report high aWERCAP scores. Depressive disorders may 
also sometimes be associated with mood lability or irritabil-
ity, although the majority of the aWERCAP question items 
would be unlikely to be endorsed by affected individuals. It is, 
therefore, expected that the aWERCAP alone would result in 
high false positive rates for BPD in community surveys, and 
would be insufficient to identify affected individuals. However, 
the aWERCAP may be suitable as an initial screening tool 
that would identify individuals who may require clinical or 
structured assessments.
For the pWERCAP, a cutoff score of 13 was associated with 88% 
sensitivity, 82% specificity, 83% PPV, and 87% negative predictive 
value for SCZ diagnosis in our study sample. This score seemed 
TaBle 4 | logistic regression analysis of Werc screens for diagnosis, with control or schizophrenia group as reference category.
Predictor β se β Wald’s χ2 df p eβ (odds ratio)
Bipolar disordera
Constant  −6.446 1.721 14.033 1 <0.001
aWERCAP 0.279 0.078 12.956 1 <0.001 1.322
pWERCAP 0.282 0.165 2.915 1 0.134 1.326
WERC stress −0.028 0.018 2.241 1 0.973 0.973
Substances used 0.343 0.222 2.390 1 0.122 1.409
schizophreniaa
Constant −2.310 1.210 3.647 1 0.056
aWERCAP −0.074 0.083 0.802 1 0.370 0.928
pWERCAP 0.520 0.170 9.358 1 0.002 1.682
WERC stress −0.020 0.020 1.038 1 0.308 0.980
Substances used 0.107 0.281 0.146 1 0.702 1.113
Bipolar disorderb
Constant −4.136 1.683 6.042 1 0.014
aWERCAP 0.353 0.096 13.521 1 <0.001 1.424
pWERCAP −0.237 0.063 14.073 1 <0.001 0.789
WERC stress −0.007 0.013 0.297 1 0.583 0.993
Substances used 0.236 0.246 0.914 1 339 1.266
Test χ2 df p
Overall model evaluation
Likelihood ratio test 156.555 8 <0.001
Goodness-of-fit test
Pearson 153.307 190 0.976
aResults of multinomial logistic regression predicting diagnosis. Cox and Snell R2 = 0.78, Nagelkerke R2 = 0.886, McFadden R2 = 0.706. Healthy controls were treated as the 
reference group in the above analysis.
bSchizophrenia was treated as the reference category in the above analysis for comparison against the bipolar group.
FigUre 4 | Mean WercaP stress screen individual item scores in each diagnostic group, with standard error bars. x-axis = individual Stress Screen 
items, y-axis = mean Stress Screen scores for each item.
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low, considering that in our previous study (22), a score of >30 
was found to best correlate with risk for developing a psychotic 
disorder using a gold standard of psychosis-risk assessment. 
Thus, a higher score would be expected in SCZ patients. One 
explanation for this discrepancy is that our study population was 
largely medicated and stable and, therefore, would exhibit milder 
FigUre 5 | WercaP screen receiver operating characteristic (rOc) curve and area under the curve (aUc) for detecting (a) bipolar disorder and (B) 
schizophrenia.
TaBle 5 | rOc curve analysis for WercaP and diagnosis.
cutoff sensitivity specificity PPV nPV
aWercaP pWercaP aWercaP pWercaP aWercaP pWercaP aWercaP pWercaP
0 100.00 100.00 0.00 0.00 50.0 50.0 n/a n/a
1 100.00 94.00 14.00 51.00 54.0 65.7 100.0 89.5
2 100.00 94.00 15.00 51.00 54.0 65.7 100.0 89.5
3 100.00 94.00 24.00 51.00 57.0 65.7 100.0 89.5
4 100.00 94.00 29.00 55.00 58.0 67.6 100.0 90.2
5 100.00 94.00 36.00 60.00 61.0 70.1 100.0 90.9
6 100.00 94.00 41.00 64.00 63.0 72.3 100.0 91.4
7 100.00 94.00 42.00 69.00 63.0 75.2 100.0 92.0
8 100.00 91.00 45.00 73.00 65.0 77.1 100.0 89.0
9 100.00 91.00 47.00 73.00 65.0 77.1 100.0 89.0
10 100.00 91.00 47.00 75.00 65.0 78.4 100.0 89.3
11 100.00 91.00 48.00 76.00 66.0 79.1 100.0 89.4
12 100.00 88.00 55.00 82.00 69.0 83.0 100.0 87.2
13 100.00 88.00 56.00 82.00 69.0 83.0 100.0 87.2
14 97.00 82.00 61.00 84.00 71.0 83.7 95.0 82.4
15 94.00 79.00 61.00 87.00 71.0 85.9 91.0 80.6
16 94.00 79.00 61.00 87.00 71.0 87.0 91.0 81.0
17 91.00 79.00 64.00 88.00 72.0 88.0 88.0 81.00
19 91.00 76.00 67.00 90.00 73.0 88.4 88.0 78.9
20 91.00 74.00 71.00 90.00 76.0 88.1 89.0 77.6
21 86.00 68.00 71.00 90.0 75.0 87.0 84.0 74.0
22 80.00 65.00 71.00 90.0 73.0 87.0 78.0 72.0
23 77.00 62.00 73.00 90.0 74.0 86.0 76.0 70.0
25 77.00 59.00 85.00 93.00 84.0 89.4 79.0 69.4
26 66.00 59.00 89.00 94.00 86.0 91.0 72.0 70.0
30 40.00 53.00 91.00 97.00 82.0 94.6 60.0 67.4
35 17.00 44.00 97.00 97.00 85.0 93.6 54.0 63.4
40 11.00 35.00 100.00 99.00 100.0 97.2 53.0 60.4
45 0.00 18.00 100.00 99.00 n/a 94.7 50.0 54.7
Values shown reflect the aWERCAP’s predictive capability of bipolar disorder and the pWERCAP’s ability to predict schizophrenia. Bolded figures indicate values associated with 
recommended cutoff points.
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symptoms than untreated patients or individuals. Although the 
WERCAP Screen was intended to elicit chronic or lifetime symp-
toms, it is plausible that individuals who have been psychiatrically 
stable could nevertheless underestimate their symptom severity. 
Thus, we believe that a score of 13 may be too conservative a cutoff 
in community settings, and would likely identify individuals 
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without any significant psychopathology. Psychotic-like experi-
ences are relatively common, especially at younger ages, and 
most with such experiences never develop psychotic disorders 
(93–96). For screening individuals with psychotic disorders in an 
unmedicated population, a higher cutoff score would, therefore, 
likely be more specific.
Contrary to our hypothesis, the Stress Screen score and num-
ber of common substances (tobacco, coffee, other caffeinated 
beverages, alcohol, and cannabis) were not significant predictors 
of diagnostic category, suggesting that these characteristics are 
non-specific to psychiatric diagnoses. This is not entirely surpris-
ing, as multiple other psychiatric disorders, including depression, 
anxiety, and externalizing disorders have been associated with 
psychosocial stress (97, 98) and substance use (99, 100). With 
regard to substance-use assessment, it should be noted that the 
Substance Screen by default captures current substance-use fre-
quency. It is, thus, conceivable that lifetime exposure to specific 
substances would be more predictive of BPD or SCZ than recent 
exposure. Diagnoses of SUDs frequently precede onset of SCZ 
and BPD (24). Certain substances are specifically associated 
with symptom onset or exacerbation. For example, cannabis use 
increases the risk of subsequent mania (101) and psychosis (102). 
Substance use has also been associated with earlier onset of mania 
(36, 103) and psychosis (104). A meta-analysis found that can-
nabis and unspecified substance use significantly increased age of 
onset of psychosis by 2.70 and 2.00 years, respectively, compared 
to non-substance-using controls (105). Substance abuse has also 
been reported to predict conversion to psychosis in a population 
at high clinical risk (106).
Our study provides an initial investigation of the utility of 
three recently developed screening instruments in identifying 
SCZ and BPD. Accurately diagnosing these medical disorders 
would, however, continue to require clinical or structured 
assessments, as established diagnostic criteria are complex, often 
involving multiple symptom categories (e.g., positive, negative, 
and disorganization symptoms for SCZ), specific duration of 
symptoms, and diagnostic exclusions (107, 108); thus, screen-
ing questionnaires should not be expected to be sufficient for 
diagnosis. Nevertheless, they can be useful for identifying 
individuals who may require further assessment. A limitation to 
our study is that it was conducted using a moderately small-sized 
sample. Furthermore, the study population was not representa-
tive of the community, where a wider range of psychopathologies 
exist which could make identifying bipolar or psychotic disorders 
more difficult. Thus, larger studies in diverse settings would be 
needed to adequately test the psychometric properties of these 
instruments. Nonetheless, this study demonstrates the potential 
of the WERC Screen as a screening tool for BPD and SCZ, espe-
cially in areas with limited access to a trained psychiatrist, or in 
settings where conducting a detailed interview is not feasible. 
Well-validated, self-report instruments could play an increasing 
role in mental health care in the future. There are relatively few 
mental health providers, with primary care providers providing 
a greater proportion of mental health care while faced with 
increasing time constraints (109). Screening for mental illness 
could also be useful in schools to identify individuals early 
when intervention could diminish the burden on the illness 
and improve functioning. Developing and validating improved 
screening tools for various aspects of psychopathology are, 
therefore, highly recommended.
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